Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus.

Abstract

Diabetes is a global health concern that has affected almost 415 million people globally. Bromocriptine is a dopamine D2 agonist, which is a Food and Drug Administration (FDA)-approved drug to treat type 2 diabetes mellitus (T2DM) patients. However, it is considered that a novel treatment therapy is required which can be used in the treatment of diabetes with or without other antidiabetic agents. Dopamine agonists are usually used in neurological disorders like Parkinson's disease (PD), restless leg syndrome, and hyperprolactinemia. However, dopamine agonists including bromocriptine and cabergoline are also effective in reducing the glycemic level in T2DM patients. Bromocriptine was formerly used for the treatment of PD, hyperprolactinemia, and restless leg syndrome, but now it is used for improving glycemic levels as well as reducing free fatty acids and triglycerides. In addition, cabergoline has been found to be effective in glycemic control, but this drug is yet to be approved by the FDA due to its limitations and lack of study. Findings of the clinical trials of bromocriptine have suggested that it reduces almost 0.4-0.8% glycated hemoglobin and cardiovascular risk by 40% in insulin-resistant patients. Moreover, the safe use of bromocriptine in obese T2DM patients makes it a more attractive option as it causes weight loss. Indeed, bromocriptine is a novel therapy for T2DM patients, as its mechanism of action is unique in T2DM patients with minimal adverse effects. This review summarizes the potential of dopamine agonists in the treatment of T2DM.

• Authors: Md Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md Sohanur Rahman, Fouad Damiri, Mohammed Berrada, Md Habibur Rahman
• Journal: Environmental science and pollution research international (Environ Sci Pollut Res Int) Vol. 29 Issue 31 Pg. 46385-46404 (Jul 2022) ISSN: 1614-7499 [Electronic] Germany
• PMID: 35486279 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Chemical References

• Dopamine Agonists
• Bromocriptine
• Cabergoline

Topics

• Bromocriptine (pharmacology, therapeutic use)
• Cabergoline (therapeutic use)
• Diabetes Mellitus, Type 2 (chemically induced, drug therapy)
• Dopamine Agonists (pharmacology, therapeutic use)
• Humans
• Hyperprolactinemia (chemically induced, drug therapy)
• Parkinson Disease
• Restless Legs Syndrome (chemically induced, drug therapy)